Follicular lymphoma (FL) is a common subtype of indolent (slow-growing) B-cell non-Hodgkin lymphoma originating from the germinal center B-cells. It typically follows a chronic course characterized by multiple relapses and remissions. While many patients are asymptomatic at the time of diagnosis, the disease is frequently widely disseminated throughout the lymphatic system. The molecular hallmark of follicular lymphoma is the chromosomal translocation t(14;18)(q32;q21), which results in the constitutive overexpression of the BCL2 protein, an anti-apoptotic factor that allows for the accumulation of malignant cells. Although FL is highly responsive to initial therapy with monoclonal antibodies and chemotherapy, it is generally considered incurable with conventional treatments. A clinically significant minority of cases (approximately 2-3% per year) may undergo histological transformation to a more aggressive malignancy, such as diffuse large B-cell lymphoma (DLBCL), which carries a poorer prognosis.
Specify the Grade of Follicular Lymphoma
Example: Patient with chronic Follicular Lymphoma Grade 2 involving multiple lymph node regions. Current status is active disease undergoing second-line therapy with Obinutuzumab. The specific grade is critical for defining the clinical course from Grade 1 (indolent) to Grade 3B (aggressive). This documentation supports HCC 11 risk adjustment by confirming active malignancy status.
Billing Focus: Documentation of the specific WHO grade (1, 2, 3A, or 3B) allows for transition from C82.90 to more specific codes like C82.10 or C82.20.
Document Precise Anatomic Nodal and Extranodal Sites
Example: Follicular lymphoma, unspecified grade, with documented involvement of the axillary lymph nodes and secondary involvement of the spleen. No evidence of bone marrow involvement on recent trephine biopsy. The presence of splenic involvement (C82.97) increases the severity profile compared to unspecified sites (C82.90).
Billing Focus: Anatomic specificity (e.g., axilla, neck, inguinal region) is required to move beyond the .90 unspecified site designation.
Distinguish Between Active Disease and Remission Status
Example: Follicular lymphoma of unspecified site, currently in complete clinical remission following R-CHOP chemotherapy. Patient is now on maintenance Rituximab every 8 weeks. Continued coding of the malignancy is appropriate as long as the patient is receiving active maintenance therapy or surveillance for a chronic condition.
Billing Focus: Use Z85.72 (Personal history of non-Hodgkin lymphoma) only when treatment is finished and there is no evidence of disease; otherwise, use the C82 code.
Identify Transformation to Aggressive Lymphoma
Example: Patient with a 5-year history of Follicular Lymphoma, unspecified site, now presenting with rapidly enlarging cervical mass. Biopsy confirms histological transformation to Diffuse Large B-cell Lymphoma (DLBCL). Both the underlying follicular component and the transformed DLBCL component must be documented to reflect the change in clinical management.
Billing Focus: Transformation requires a shift in coding to the C83 series (Diffuse non-Hodgkin lymphoma) which has different billing implications.
Record Comorbidities Related to Lymphoma Treatment
Example: Follicular lymphoma, unspecified, currently stable. Patient has developed secondary hypogammaglobulinemia (D80.1) due to long-term B-cell depletion from Rituximab therapy, requiring monthly IVIG infusions. Documentation of this complication justifies the complexity of the visit and the medical necessity of auxiliary treatments.
Billing Focus: Capturing treatment-induced complications like neutropenia or anemia allows for additional diagnosis codes that support higher-level E/M coding.
Used for routine surveillance visits where no new symptoms are present and disease is stable.
Applied when the physician is managing chemotherapy side effects or adjusting treatment plans for active follicular lymphoma.
Necessary when discussing transformation to aggressive disease or life-threatening complications of treatment.
Essential for determining Stage IV involvement which changes the treatment paradigm.
The standard procedure code for administering systemic therapy like Rituximab.
PET/CT is the gold standard for mapping nodal involvement in follicular lymphoma.
Core needle biopsies are often insufficient; excisional biopsy is preferred for architectural grading of follicular lymphoma.
Commonly billed alongside chemotherapy for supportive care medications like antiemetics.
Required for the definitive diagnosis and grading of follicular lymphoma.
Ki-67 staining helps differentiate between low-grade and high-grade follicular lymphoma.